EN
HI

NATCO PHARMA Share price

NATCOPHARM

HealthcareLarge

841.15

17.35 (2.11%)
NSE
BSE
Last updated on 16 May, 2025 | 15:58 IST
BUYSELL
Today's High

851.00

Today's Low

819.05

52 Week Low

726.80

52 Week High

1639.00

The current prices are delayed, login to your account for live prices

Natco Pharma Chart

NATCO PHARMA Fundamentals

P/E Ratio

8.51

P/B Ratio

2.16

Div. Yield

1.13

Sector P/E

41.98

Sector P/B

4.77

Sec. Div. Yield

0.33

NATCO PHARMA Resistance and Support

Pivot 826.68

Resistance

First Resistance

832.11

Second Resistance

840.43

Third Resistance

845.86

Support

First Support

818.36

Second Support

812.93

Third Support

804.61

NATCO PHARMA Futures & Options

Data Not Found

NATCO PHARMA Shareholding Pattern

    Total Promoters
    Segment
    Percent

    Total Promoters

    49.62%

    Mutual Fund

    1.92%

    Insurance

    3.33%

    Foreign Institutional Investors

    17.94%

    Domestic Institutional Investors

    0.32%

    Retail

    26.88%

    Others

    -0.01%

    Total Promoters
    MAR '24
    49.71%
    JUN '24
    49.71%
    SEP '24
    49.62%
    DEC '24
    49.62%

    NATCO PHARMA Corporate Actions

    DateAgenda
    2025-05-28Audited Results
    2025-02-18-
    2025-02-12Quarterly Results & Interim Dividend
    DateEvent TypeAgenda
    2025-05-28Board MeetingAudited Results
    2025-02-18Dividend-
    2025-02-12Board MeetingQuarterly Results & Interim Dividend

    NATCO PHARMA News

    Microsoft India buys Rs 181.25 crore land parcel near Hyderabad from Natco Pharma

    Dec 05 2024 05:41:58

    Stocks in news: Waaree Renewable, Godrej Properties, Vedanta, PCBL, Natco Pharma

    Nov 28 2024 06:41:50

    Natco Pharma Q2 Results: Net profit shoots up 83% to Rs 676 crore

    Nov 12 2024 17:42:01

    Natco Pharma Q2 net profit jumps 83% to Rs 676 crore

    Nov 12 2024 17:36:55
    Read More

    About NATCO PHARMA AboutThe

    NSE : 3918  
    BSE : 524816  
    ISIN : INE987B01026  

    NATCO PHARMA LTD. was incorporated on 19th September 1981in Andhra Pradesh as a Pvt. Ltd. Company as NATCO FINEPHARMACEUTICALS P. LTD. and became a deemed Public Companywith effect from 1st July 1992 under Section 43A of theAct. Subsequently it changed its name to NATCO PHARMALTD. on 18th February 1993 and received change of namecertificate.The Company began operations in 1984 with an objective tomanufacture conventional and Timed Release Dosage forms oflife savings drugs. The company''s factory is located 35km.away from Hyderabad on Bangalore Highway No. 7. It hasfollowing capacities to manufacture a wide range oftablets capsules liquids and dry powders using automatedequipments:-------------------------------------------------- Capacity (Units p.a.) (One shift basis)--------------------------------------------------Tablets 18 CroresCapsulesTimed Release 30 CroresAntibiotics 12 CroresLiquids 1.20 Crore bottles (60 KL)Dry Syrups 0.30 Crore bottlesAerosol 0.24 Crore containers---------------------------------------------------Indigenisation of Microdialysis Cell technology for variousdosage forms was taken up as a challenge and Company hadintroduced Antihistaminic Antianxiety AntiasthmaticCardiac Drugs into Indian Market for the first time insustained action dosage forms. The major productsmanufactured by the company are as follows:FLOCY (CIPROFLOXACIN HCI)NATCOCILLIN (AMPICILLIN)NATAMOX (AMOXYCILLIN)TR PHYLLIN (THEOPHYLLINE)BETACAP TR (PROPRANOLOL HCI)CARDICAP TR (ISOSORBIDE-Dl-NlTRATE)IBUBID TR (IBUPROFEN)NACLO TR (DICLOFENAC SODIUM)CAMRELEASE TR (DIAZEPAM)CEPIAM TR (CHLORPHENIRAMINE MALEATE)POTRELEASE TR (POTASSIUM CHLORIDE)COLDACT (PHENYL PROPANOLAMINE)HCI + CHLORPHENlRAMINE MALEATE)The Company holds the necessary licences issued by the DrugControl Authorities for the manufacture of these drugs atits existing plant at Kothur Mahaboobnagar. The turnoverof the unit increased progressively; the turnover which wasat Rs. 730 lacs for the year 1989-90 has grown to Rs. 3689.24 Lacs for the year 1993-94.The Company has pioneered Timed Release Technology in Indiaby introducing Multi-unit Multi-layered System for thefirst time in India in the year 1985. The company''sformulation Rubinat is ranked second in the Anticancer DrugSegment and first in the Anthracyclines Segment on thebasis of turnover of 1993-94. The Company has been awardedImport Substitution Award (1986) for Timed ReleaseTechnology. It has well equipped Research and Developmentfacilities manned by qualified Scientists. Itsformulations are exported to the CIS States VietnamHongkong China Netherlands Nigeria Tanzania and Kenya.The Annual average exports sales for the last three yearsis 21% of turnover. The Export turnover details for last 3 years are as follows: (Rs. in lakhs)-----------------------------------------------------Year Total Export % to Total Turnover Turnover-----------------------------------------------------1991-92 1169.36 47.39 4%1992-93 2840.00 739.86 26%1993-94 3542.74 1168.64 33%Sept. ''94 3402.59 1740.15 51%(6 months)-----------------------------------------------------The Company is a recipient of WHO Certificate formaintaining good manutacturing practices. The Company isone of the contract manufacturers in the pharmaceuticalsindustry in India and manufactures products for companiesincluding Ranbaxy Laboratories Ltd. Eskayef Ltd. ParkeDavis (I) Ltd. Fulford India Limited Cadila Ltd. JohnWyeth India Ltd. ICI Ltd. and SOL Pharmaceuticals Ltd.

    NATCO PHARMA Management

    NamePosition
    Mr. V C Nannapaneni Chairman & Ind.Director
    Mr. Rajeev Nannapaneni Director & CEO
    Mr. P S R K Prasad Director & Exe. VP (Corp. Engg. Services)
    Dr. D Linga Rao Director & President (Tech. Affairs)
    Dr. Pavan Ganapati Bhat Director
    Read More

    NATCO PHARMA FAQs

    NATCO PHARMA शेयर का खरीद मूल्य 841.15 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

    NATCO PHARMA शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

    NATCO PHARMA शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 8.51 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

    NATCO PHARMA शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.16 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

    NATCO PHARMA शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 4.77 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

    NATCO PHARMA का मार्केट कैप 15065.83 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

    NATCO PHARMA शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 1639.00 और 726.80 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

    NATCO PHARMA Share Key Metrics

    Volume
    7.34 L
    Market Cap
    15065.83 CR
    LTQ@LTP
    100@841.15
    ATP
    835.48
    Var Margin
    20.48 %
    Circuit Range
    659.05-988.55
    Delivery %
    64.9 %
    Value
    61.34 CR
    ASM/GSM
    No
    Market Lot
    1